Viking Therapeutics struggles with FDA approval and scaling up. Find out why VKTX stock’s path remains uncertain, despite its ...

Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $34.94 which represents a slight increase of $0.89 or 2.61% from the prior close of $34.05. The stock opened at $33.85 and ...

BTIG analyst Justin Zelin reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of ...

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...

Viking has long been viewed as a takeover target, given the positive data from early VK2735 trials. The company’s most recent ...

Viking (VKTX) is in the midst of a phase 2a dosing trial of its oral obesity drug VK2735, with a data readout expected in the second half of the year. The company is expected to launch a phase 3 trial ...

Palantir Technologies (NASDAQ:PLTR) has been described as the best pure-play stock in artificial intelligence. The market ...

Viking Therapeutics (NASDAQ:VKTX), currently trading at $32.65, remained in focus as H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating with a price target of $102.00. According to ...

Viking Therapeutics investors face challenges as stock plummets, cash runway helps but betting on early stage biopharma ...

Viking Therapeutics Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -34.83%. The profit margin, also known as the revenue ratio or gross profit ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on VKTX stock, giving a Buy rating on January 9.Stay Ahead of the ...